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Our aim was to assess the phenotype of T-cell subsets in patients with ankylosing spondylitis (AS), a chronic inflammatory
rheumatic disease. In addition, we also tested short-term T-cell activation characteristics. Measurements were done in 13 AS
patients before and during the intravenous therapy with anti-TNF agent infliximab (IFX). Flow cytometry was used to determine
T-cell subsets in peripheral blood and their intracellular signaling during activation. The prevalence of Th2 and Th17 cells
responsible for the regulation of adaptive immunity was higher in AS than in 9 healthy controls. Although IFX therapy improved
patients’ condition, immune phenotype did not normalize. Cytoplasmic andmitochondrial calcium responses of CD4+ and CD8+
cells to a specific activation were delayed, while NO generation was increased in AS. NO generation normalized sooner upon IFX
than calcium response. These results suggest an abnormal immune phenotype with functional disturbances of CD4+ and CD8+
cells in AS.
1. Introduction
Ankylosing spondylitis (AS) is a chronic inflammatory
rheumatic disease, the best characterized of the diseases
belonging to the concept of spondylarthritides. It aﬀects
mainly the axial skeleton and the sacroiliac joints [1]. In
time, the chronic inflammation of the spine (spondylitis)
causes extra bone formation and eventually leads to the
fusion of the vertebrae (ankylosis) [2]. The pathogenesis of
AS is still unclear, but it is considered to be an autoimmune
disease with a strong association with the MHC class I
genetic marker HLA-B27 [3]. In any stages of the disease,
autoimmune reactions can be associated with peripheral-
arthritis, enthesitis, and extra-articular manifestations such
as inflammations in the eye, the gastrointestinal tract, and the
heart [4], indicating that AS is a systemic immune-mediated
disease. This is supported by the number of alterations found
in lymphocyte subgroups in peripheral blood.
Specifically, increased numbers of circulating Th2 helper
lymphocytes [5] as well as increased numbers of Th17
cells [6] were reported in AS. Regulatory T-cells as major
suppressors of the immune system show decreased preva-
lence, in the blood of AS patients indicating that their
lack may contribute to the pathogenesis of the disease
[7]. Along the alterations observed in cell prevalence one
can assume that T-cell activation properties may also be
altered in AS. In rheumatoid arthritis (RA), a further
common example of chronic inflammatory arthritides, T-
lymphocytes present an increase in intracellular nitric oxide
(NO) production along with increased cytoplasmic Ca2+
concentrations [8]. This finding raised the notion that some
functional alterations of T-lymphocytes were indeed present
in autoimmune rheumatic disorders and would contribute
to ongoing inflammation risk and progression of the disease.
However, to date, no studies have been performed to
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characterize functional characteristics of short-term T-cell
activation in AS.
Eﬀective therapy in AS includes the administration
of nonsteroidal antiinflammatory drugs (NSAIDs) and, in
unresponsive patients, the use of anti-tumor necrosis factor
(TNF)-α agents such as infliximab (IFX). IFX is a chimeric
anti-TNF antibody that has been shown to be highly eﬀective
for the treatment of AS. Although NSAID treatment has
only a symptomatic eﬀect and probably does not alter
the disease course, IFX targets the specific inflammatory
processes of the disease, and thus may potentially influence
disease progression [9]. In addition to its action on soluble
TNF-α, an increasing body of evidence supports the eﬀect of
IFX on immune cell prevalence [10–12]. However, no data
regarding the impact of IFX on adaptive immune phenotype
were reported in AS.
The aim of our comprehensive study was to assess the
prevalence of major regulatory cells of adaptive immunity,
and also to investigate the short-term T-cell activation
characteristics in AS before and during IFX therapy.
2. Materials and Methods
2.1. Patients. Eleven male and two female patients with
active AS meeting the modified New York criteria [13]
were enrolled to the study. The age of the patients was
(mean ± SD) 43.7 ± 9.2 years, and disease duration was
10.0 ± 5.4 years. Inclusion criteria were (1) Bath ankylosing
spondylitis disease activity index (BASDAI) [14] higher than
4, (2) no response to 2 types of NSAIDs and (3) HLA-B27
positivity. Each of the patients was candidate for IFX therapy.
The patients are given infliximab at a dose of 5mg/kg bw
intravenously on week 0, 2, and 6 then on every 8th week.
Exclusion criteria were any significant comorbidity and the
use of any drug excluding NSAID and a proton pump
inhibitor. Nine male age-matched healthy volunteers (39.6±
6.5 years) served as controls. Written informed consent was
obtained from each participant. The work was approved by a
local ethical committee, and it was conducted in accordance
with the Declaration of Helsinki (1964).
2.2. Cell Preparation. 24mL of lithium-heparin anticoagu-
lated blood was taken from all participants. In AS patients,
blood samples were taken at 3 distinct time points: just before
starting IFX when each of them was on NSAID therapy alone
then on Week 2 and 6 after initiation of IFX therapy. Periph-
eral blood mononuclear cells (PBMCs) were separated with
gradient centrifugation using Ficoll-Paque (GE Healthcare
Life Sciences, Pittsburgh, PA, USA) and washed twice with
Phosphate Buﬀered Saline pH 7.4 (PBS, Central Pharmacy
of Semmelweis University, Budapest, Hungary). 20% of the
PBMCs (approximately 5 × 106 cells) was resuspended in
PBS and used for cell surface staining, while 80% (2 × 107
cells) was resuspended inmodified RPMI (Sigma-Aldrich, St.
Louis, Mo, USA) medium (the Ca2+ concentration was set to
2mM) for intracellular measurements.
2.3. Surface Staining. To characterize T-cell subset prevalence
values, PBMCs were stained with fluorescent antibodies
(Becton Dickinson, San Diego, Calif, USA) against cell sur-
face markers according to the manufacturer’s instructions.
Samples were measured within 1 hour after staining; at least,
300,000 events were recorded for each acquisition.
Cell types were defined as: helper T-cells (CD4+),
cytotoxic T-cells (CD8+), Th1 cells (CD4+CXCR3+), Th2
cells (CD4+CCR4+), Th17 cells (CD4+CCR4+CCR6+),
regulatory T-cells (Tregs; CD4+CD25+CD127−), naive T-
cells (CD4+CD45RA+ and CD8+CD45RA+), and mem-
ory/eﬀector T-cells (CD4+CD45RO+ and CD8+CD45RO+).
The prevalence of CD4+ and CD8+ cells expressing early
and late activation markers (i.e., CD25, CD69, and HLA-DR,
resp.) was also determined.
2.4. Intracellular Staining. In order to characterize intracel-
lular processes associated with a specific T-cell stimulation,
each specimen marked with CD4+ and CD8+ surface mark-
ers was loaded with Fluo3AM, Rhod2-AM,Dihydroethidium
and DAF-FM diacetate (Molecular Probes, Carlsbad, Calif,
USA) sensitive to cytoplasmic Ca2+ levels, mitochondrial
Ca2+ levels, superoxide generation and nitric oxide pro-
duction, respectively. Staining conditions were identical to
those recently reported [15]. The changes in fluorescent
signals were monitored up to 10 minutes after the addition
of 20 μg/mL in final concentration of phytohaemagglutinin
(PHA) (Sigma-Aldrich, St. Louis, Mo, USA), a specific
activator of T-cells.
2.5. Equipment and Statistical Analysis. All measurements
were performed on a BD FACSAria flow cytometer (Becton
Dickinson, San Jose, Calif, USA). Cell prevalence values
were determined with conventional gating using FACSDiVa
software (Becton Dickinson, San Jose, Calif, USA).
The kinetic parameters of intracellular processes were
determined using R (R Foundation for Statistical Comput-
ing, Vienna, Austria) as follows. Measurement timeframe
was divided into 100 time intervals of equal length, and
the medians of fluorescent values were calculated in each
interval. Lowess smoothing method was applied to the
median values, and each value was related to thatmeasured at
the beginning of the experiment (the resulting values became
relative parameter values, rpv). The following parameters
were calculated from the rpv values: area under the curve
(AUC), maximum value (Max) and time to reach maximum
(tmax) (Figure 1). One unit (u) of the AUC value is defined
as one rpv in one second. Detailed explanation of these
parameters can be found in our previous work [16].
Further statistical analysis was based on the values
of these parameters and was performed using Statistica
7 software package (Statsoft, Tulsa, Okla, USA). For the
comparison of controls and patients before IFX, a Mann-
Whitney test was used, while data obtained on Week 2 and
6 were compared to those measured before IFX using paired
Wilcoxon test. All data are given as median and [interquartile
range]. P < 0.05 was considered significant.
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Figure 1: Schematic demonstration of characteristics changes of
intracellular processes following PHA activation of lymphocytes.
AUC: area under the curve, Max: maximum value, tmax: time to
reach maximum.
3. Results and Discussion
Originally, 13 patients were enrolled; on week 2 and 6,
11, and 8 patients provided blood samples, respectively. 2
patients did not return after the initial IFX administration
because of technical reasons (moving to a diﬀerent region),
while the others did not attend appointments at the required
time.
At the beginning, BASDAI was ≥5 in each AS patient
(median [interquartile range]: 6.88 [6.07–7.6]. After 6 weeks
of IFX therapy, it decreased significantly: 1.79 [0.60–3.83],
P < 0.0001.
3.1. Cell Prevalence Values. We found several important
diﬀerences in cell prevalence values between AS with or
without IFX and healthy controls (Table 1). The overall
prevalence of CD4+ cells within lymphocytes increased in
AS, while that of expressing CD25 decreased. In AS, Th1
prevalence values increased by approximately 30 per cent,
while Th2 prevalence was double, resulting in a skewness of
Th1/Th2 ratio to a Th2 direction. Th17 prevalence increased
by 70 per cent, while Treg numbers were comparable to that
in controls.
During IFX-treatment, these abnormalities did not dis-
appear. Instead, the prevalence of naive cells on Week 2 and
6 decreased, while the prevalence of memory/eﬀector cells
increased on Week 6.
In general, CD8+ prevalence was comparable in patients
and controls irrespectively of IFX therapy.
3.2. Functional Characteristics. CD4+ and CD8+ cells pre-
sented with a delayed increase in cytoplasmic Ca2+ levels after
activation in AS compared to controls (Table 2, Figure 2).
Mitochondrial Ca2+ kinetics also changed in a similar man-
ner in CD8+ cells (Figure 2). The amount of NO generation,
max and time to reach max NO levels were significantly
higher in CD4+ and CD8+ cells of AS patients (Figure 3).
Superoxide generation of T-cells did not diﬀer between AS
and controls. (For data on AUC levels see Table 2; additional
information on comparable tmax and Max levels is available
upon request.)
With IFX, therapy the delay in CD4+ cytoplasmic Ca2+
levels did not normalize in AS. For CD8+ cells, cytoplasmic
and mitochondrial Ca2+ kinetics during activation normal-
ized by week 6 on IFX (but not on week 2). NO kinetics
became comparable in AS patients to that in controls even
after 2 weeks of IFX therapy.
3.3. Discussion. AS is a chronic, systemic disorder exhibiting
autoimmune reactions particularly against large joints and
the axial skeleton [9]. The pathogenesis is still unclear, but
both innate and adaptive immune responses could have a
role in disease development [1].
Diﬀerent T-lymphocyte subpopulations are implicated
in AS [17]. Previous studies extensively investigated the
prevalence of diﬀerent T-cell subtypes in AS in diﬀerent
body fluids. A number of papers consistently reported that
peripheral CD4+ [18] and CD8+ [19] cell numbers in blood
are increased. In line with these data, we also observed higher
than normal CD4+ prevalence in AS patients’ blood.
Simultaneously with increased CD4+, Th1 and Th2
prevalence also increased. This finding supports earlier
observations that indicated higher than normal Th2 [5]
activity in AS. In addition to CCR4+, the prevalence of
CXCR3+ cells were also found to be increased, but to a less
extent, leading to a skewness to Th2 direction. Therefore
our results relying on cell surface markers reinforce previous
data based on the cytokine producing capability of T-cells
suggesting a Th2 dominance in AS [20]. (The CXCR3
and CCR4 markers are increasingly accepted as surrogate
markers of Th1 and Th2 cells, resp. [12].)
We also tested the prevalence of Th17 and Treg cells
due to their central role in the regulation of T-cell subset
functions. The clinical importance of Treg cells in autoim-
mune disorders are underlined by their reduced prevalence
in a number of conditions [21], particularly when the
prevalence of proinflammatory Th17 cells is increased [22,
23]. For AS, Wu et al. demonstrated that Th17/Treg cell
ratios are increased and speculated that this abnormality in
immune phenotype may be a contributing factor to disease
development [7]. In our patients, we also found a skewness
of Th17/Treg ratios to Th17 supporting this theory.
The discrepancy between the normal Treg prevalence
found in our study and the lower Treg reported earlier may
be partly due to diﬀerent techniques used for the assessment
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Table 1: Prevalence and ratios of T-cell subsets in ankylosing spondylitis patients before and during infliximab (IFX) therapy.
Members of adaptive
immunity
Healthy controls (n = 9) Before IFX therapy
(n = 13)
Week 2 after IFX therapy
(n = 11)
Week 6 after IFX therapy
(n = 8)
CD4+ 35.80 [29.43-40.95] 42.7 [38.35–48.65]∗ 47.10 [43.00–49.10]∗ 44.30 [42.15–48.85]∗
CD4+CD45RA+ 49.50 [40.68–61.68] 50.80 [45.20–65.95] 50.90 [36.20–55.40]# 42.55 [39.55–60.78]#
CD4+CD25+ 7.55 [6.20–7.88] 4.82 [4.22–5.42]∗ 3.92 [3.60–4.85]∗ 4.35 [4.04–4.98]∗
CD4+CD69+ 3.23 [2.83–4.48] 3.05 [2.72–3.28] 3.04 [2.69–3.43] 2.88 [2.21–3.36]
CD4+HLA-DR+ 2.8 [2.53–3.81] 3.03 [2.09–3.46] 1.95 [1.56–2.33] 2.89 [2.21–3.51]
CD4+CD45RO+ 42.95 [33.33–49.65] 41.50 [29.40–49.55] 45.50 [37.80–54.60] 47.45 [33.10–54.78]#
Th1 9.81 [8.95–12.53] 12.90 [11.75–13.80]∗ 14.00 [11.50–15.70]∗ 13.80 [12.43–18.83]∗
Th2 4.54 [4.19–4.84] 9.18 [7.32–11.45]∗ 8.70 [7.98–11.30]∗ 10.90 [8.32–12.50]∗
Th1/Th2 ratio 2.38 [1.95–2.64] 1.31 [1.06–1.85]∗ 1.40 [1.16–1.83]∗ 1.38 [1.11–1.72]∗
Th17 0.69 [0.60–0.77] 1.18 [1.02–1.69]∗ 1.2 [0.84–1.55]∗ 1.26 [0.91–1.51]∗
Treg 4.42 [3.76–5.58] 4.45 [3.57–5.51] 4.29 [3.66–5.72] 4.42 [4.05–5.24]
Th17/Treg ratio 0.14 [0.13–0.21] 0.27 [0.19–0.45]∗ 0.25 [0.17–0.39]∗ 0.29 [0.18–0.37]∗
CD8+ 18.00 [14.35–27.98] 17.70 [14.65–21.45] 18.30 [14.20–21.90] 16.65 [14.43–21.60]
CD8+CD45RA+ 62.85 [53.38–75.78] 70.30 [61.70–78.75] 69.10 [55.20–72.50] 60.20 [54.43–70.33]
CD8+CD25+ 2.84 [1.87–4.06] 2.81 [2.23–3.63] 2.85 [2.07–3.23] 3.29 [1.84–3.54]
CD8+CD69+ 4.0 [3.53–12.78] 4.88 [3.37–5.89] 3.71 [3.26–6.77] 5.06 [3.55–6.27]
CD8+HLA-DR+ 3.58 [3.10–5.31] 3.43 [2.95–4.33] 4.37 [2.93–5.15] 3.57 [2.91–5.15]
CD8+CD45RO+ 23.65 [15.90–28.15] 19.40 [14.25–28.20] 26.30 [19.10–34.90] 28.45 [18.53–40.20]
CD4/CD8 ratio 2.07 [1.32–2.83] 2.26 [2.02–3.15] 2.61 [1.99–3.21] 2.82 [1.90–3.36]
Data are expressed as median [interquartile range] ∗versus control P < 0.05; #versus before IFX P < 0.05.
of Tregs. While Wu et al. identified Tregs according to FoxP3
expression, we defined Tregs as CD4+CD25+CD127−.
Although it is in general accepted that CD127 inversely
correlates with FoxP3 in CD4+ cells [24] and that the absence
of CD127 expression can be used as an alternative to the
transcription factor FoxP3 [25], a recent study suggests that
these markers do not necessarily represent the same popu-
lation of Tregs and, therefore, likely cannot be used for the
comparison of results of studies with diﬀerent methodology
[26]. (However, when we analysed the prevalence of cells
with CD4+CD25+ positivity—that was used earlier for the
detection of Tregs—we did find decreased levels, confirming
a decrease in Tregs in AS.)
While CD45RA+ and CD45RO+ (naive and mem-
ory/eﬀector) T-cells have an important role in some autoim-
mune disorders [27], we found no diﬀerence in the preva-
lence values of these cell types between AS and healthy
controls confirming the findings of other studies [28]. In
addition, the prevalence of T-cells expressing early- and
late-onset activation markers (CD69, HLA-DR) was also
comparable in AS and controls as in other studies [29].
Overall, these results suggest that the prevalence of some
CD4+ subsets including Th1, Th2, and Th17 cells is increased
suggesting a general alteration in immune phenotype in
AS. Of note, no major alterations in CD8+ subsets were
found in AS patients. It is worth emphasizing, however, that
these results relate to peripheral blood and, therefore, do
not necessarily reflect the local conditions in aﬀected joints,
where the local immune cell numbers and ratios may be
diﬀerent.
In this study, we also followed up the cell prevalence
values during IFX therapy of AS patients. While during IFX
we observed a significant decrease in disease activity, this
change was not directly accompanied by the normalization
of CD4+ subset prevalence. Instead, the prevalence of naive
and memory/eﬀector CD4+ cells significantly altered in
an opposite manner leading to an increase in the ratio
of memory/naive cells. As the prevalence of cell types
investigated did not normalize during IFX, it is reasonable
to postulate that the prevalence of these T-cell subtypes are
not linked to clinical eﬃcacy of IFX in AS.
These results are in contrast with the eﬀects of IFX on
immune cells in other diseases. An increase in the prevalence
of CD4+ and CD8+ cells in Crohn’s disease [10], that of Tregs
[11] and Th1 committed T-cells in RA [12], was observed
during IFX treatments. The discrepancy between our results
and other studies may suggest that the impact of IFX on cell
prevalence may diﬀer between disorders.
Increased chronic TNF-α exposure is the hallmark for
many inflammatory rheumatological disorders. In AS, high
TNF-α levels have consistently been reported [30, 31]. High
TNF-α induces systemic and local inflammation leading to
the clinical signs and symptoms of AS. More recently, an
increasing amount of evidence has suggested the impact of
TNF-α on intracellular T-cell signaling [32, 33].
TCR stimulation induces Ca2+ influx and, through
inositol-1,4,5-triphosphate (IP3), the release of Ca2+ from
intracellular stores. (Almost immediately, the reuptake of
Ca2+ to endoplasmic reticulum and mitochondria is also
initiated.) This process was clearly detected in CD4+ and
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Table 2: Functional characteristics of intracellular processes in CD4+ and CD8+ cells following PHA activation in ankylosing spondylitis
patients before and during infliximab (IFX) therapy.
Parameter
Healthy controls
(n = 9)
Before IFX therapy
(n = 13)
Week 2 after IFX
therapy (n = 11)
Week 6 after IFX
therapy (n = 8)
Cytoplasmic Ca2+
CD4+
AUC (U)
63.24
[58.00–107.9]
82.43
[64.22–255.8]
93.57
[56.89–201.0]
96.21
[87.13–158.10]
Max (rpv)
1.156
[1.132–1.256]
1.268
[1.174–1.623]
1.321
[1.149–1.477]
1.254
[1.216–1.420]
tmax (s)
258.4
[192.1–283.5]
527.5 [327.9
595.3]∗
471.1
[288.2–594.3]∗
594.7
[290.5–595.5]∗
CD8+
AUC (U)
48.76
[38.53–93.22]
88.52
[54.65–327.8]
104.8
[42.14–180.8]
81.55
[58.51–407.1]
Max (rpv)
1.139
[1.089–1.262]
1.247
[1.124–1.852]
1.318
[1.120–1.434]
1.220
[1.125–1.819]
tmax (s)
228.6
[162.1–593.2]
594.3
[294.6–595.6]∗
594.4
[422.9–596.1]∗
282.7
[232.9–531.0]
Mitochondrial Ca2+
CD4+
AUC (U)
61.64
[37.97–94.43]
66.00
[41.55–95.52]
64.87
[42.90–105.4]
67.60
[49.29–104.2]
Max (rpv)
1.194
[1.121–1.272]
1.207
[1.103–1.241]
1.149
[1.114–1.281]
1.172
[1.159–1.266]
tmax (s)
594.0
[211.9–594.9]
593.3
[384.7–595.3]
595.2
[593.0–596.2]
595.1
[386.6–596.4]
CD8+
AUC (U)
106.9
[71.64–144.5]
87.79
[62.47–101.4]
71.31
[53.46–175.0]
118.8
[67.55–249.9]
Max (rpv)
1.250
[1.152–1.404]
1.187
[1.130–1.217]
1.154
[1.131–1.400]
1.259
[1.143–1.539]
tmax (s)
144.2
[121.6–160.6]
577.1
[167.8–594.2]∗
468.8
[165.3–594.7]∗
198.7
[169.8–248.4]
Nitric oxide production
CD4+
AUC (U)
3.318
[−8.315–18.84]
47.76
[1.727–97.18]∗
22.20
[−8.903–37.95]
−3.055
[−13.24–9.005]#
Max (rpv)
1.013
[1.000–1.043]
1.113
[1.011–1.282]∗
1.046
[1.000–1.081]
1.001
[1.000–1.034]#
tmax (s)
198.7
[34.55–321.8]
594.3
[228.2–594.8]∗
331.2
[0.000–556.5]
107.9
[0.000–252.5]#
CD8+
AUC (U)
−9.481
[−19.97–24.30]
41.31
[6.068–109.8]∗
9.641
[−11.20–29.92]
−11.80
[−29.93–4.094]#
Max (rpv)
1.003
[1.000–1.051]
1.099
[1.011–1.330]∗
1.025
[1.001–1.078]
1.000
[1.000–1.001]#
tmax (s)
51.08
[0.000–185.2]
594.2
[185.2–594.8]∗
289.1
[54.03–553.5]
0.001
[0.000–130.5]#
Superoxide generation
CD4+ AUC (U)
79.27
[64.68–88.90]
75.65
[70.70–92.61]
82.64
[58.40–96.68]
70.99
[56.09–83.99]
CD8+ AUC (U)
73.15
[62.21–80.33]
74.97
[61.28–98.75]
83.87
[58.13–90.74]
60.34
[51.38–85.42]
Data are expressed as median [interquartile range] ∗versus control P < 0.05; #versus before IFX therapy P < 0.05; AUC: area under the curve, Max: maximum
value, tmax: time to reach maximum.
CD8+ lymphocytes in our experiments: after a specific
stimulation of TCR with PHA cytoplasmic Ca2+ levels and,
in a parallel manner, mitochondrial Ca2+ levels increased in
CD4+ and CD8+ cells in each sample. Of note, the increase
of cytoplasmic Ca2+ levels in CD4+ and CD8+ cells from AS
is delayed compared to controls. As a consequence, mito-
chondria (at least in CD8+ cells) also presented a delayed
calcium response during short-term activation. (For CD4+
cells, the time when max calcium values in mitochondria
reached was beyond the measurement in a large number of
control and AS samples.) The delayed calcium response of
AS fits well into the observations done in in vitro tests with
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Figure 2: Time to reach maximum in cytoplasmic and mitochondrial Ca2+ levels in CD4+ and CD8+ cells following activation in healthy
controls (n = 9) and ankylosing spondylitis patients before infliximab (IFX) therapy (n = 13) then 2 and 6 weeks after initiation of IFX
(n = 11 and 8, resp.). ∗P < 0.05.
T-cells exposed to TNF-α. Church et al. reported that TNF-α
suppressed the Ca2+ peak after PHA stimulation; they have
suggested that either signalling pathways upstream of Ca2+
mobilisation or the Ca2+ signalling itself were impaired by
prolonged TNF-α exposure [33]. In AS, only one study has
been performed with a more robust analytical approach: Lee
et al. did not observe a significant diﬀerence in intracellular
Ca2+ between AS patients and normal controls in activated
peripheral blood mononuclear cells [34]. The inconsistency
between their and our results is probably due to diﬀerent
methodology and cell types investigated.
The increase in Ca2+ levels following TCR stimulation
triggers a large number of intracellular events. These include
elevated NO production [35]. There is also a negative feed-
back, as high NO levels inhibit TCR signaling by decreasing
the zeta-chain expression [36]. The eﬀect of TNF-α on
intracellular NO production, however, is rather independent
on TCR as it induces iNOS activity directly in macrophages
[37]. Therefore, in the presence of high TNF-α levels, in
addition to the decrease of calcium response in T-cells, one
can assume an increase in NO levels upon stimulation. This
theory is clearly supported by our measurements indicating
high NO levels in AS patients.
IFX is an eﬀective anti-TNF agent that suspends TNF-
mediated eﬀects. In the prospective phase of our study,
cell calcium handling (i.e, cytoplasmic and mitochondrial
calcium response upon activation) of CD8+ cells normalized
on week 6 (but not on week 2) of IFX therapy. For CD4+
cells, calcium handling remained abnormal even in the
presence of significant improvement of clinical status of AS
patients on IFX therapy. On the other hand, intracellular NO
metabolism became normal already on week 2 and remained
comparable to controls on week 6 of IFX therapy both in
CD4+ and CD8+ cells. Therefore, one can conclude that
the impact of IFX therapy on calcium handling and NO
metabolism of T-cells diﬀers. As NO kinetics in activated
T-cells normalizes much earlier than calcium-kinetics, the
major factors leading to NO abnormalities in IFX untreated
patients seem independent of those leading to abnormalities
in calcium kinetics. In addition, as the clinical condition of
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Figure 3: Nitric oxide generation kinetics in CD4+ and CD8+ cells following activation in healthy controls (n = 9) and ankylosing
spondylitis patients before infliximab (IFX) therapy (n = 13) then 2 and 6 weeks after initiation of IFX (n = 11 and 8, resp.). ∗P < 0.05
AUC: area under the curve. For details of IFX therapy, see text.
AS patients improved irrespectively of calcium kinetics, it is
also reasonable to postulate that Ca2+ handling abnormalities
of stimulated T-cells do not have a dominant role in the
development of clinical signs and symptoms in AS.
In addition to Ca2+ and NO, we also tested superoxide
generation of activated T-cells. No diﬀerence was observed
between control and AS patients with or without IFX.
4. Conclusions
In this study, we found that the prevalence of Th2 and Th17
cells responsible for the regulation of adaptive immunity is
diﬀerent between AS and healthy controls.While IFX therapy
improved the overall condition of patients, cell prevalence
abnormalities did not disappear.
Some intracellular processes that are integral parts of
lymphocyte activation are also altered in AS. These include
intracellular nitric oxide and calcium handling. There are
marked diﬀerences in the impact of anti-TNF therapy on
these processes.
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